Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, December 2014

Sort by: Newest first Oldest first A-Z Z-A

  • Capoten interactions Subscription

    11 DEC 2014 13:27

    The summary of product characteristics of Capoten (captopril; Bristol-Myers Squibb) now states that this medicine should not be used with aliskiren-containing products in patients with diabetes or renal impairment. In addition, dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is not recommended. 

  • NICE recommends Glivec for GIST recurrence Subscription

    11 DEC 2014 13:26

    The National Institute for Health and Care Excellence (NICE) has issued final guidance to the NHS recommending Glivec (imatinib; Novartis) for up to three years for people who have had a gastro-intestinal stromal tumour (GIST) removed and who are at high risk of the cancer recurring.       

  • Xagrid in the paediatric population Subscription

    11 DEC 2014 13:21

    The summary of product characteristics of Xagrid (anagrelide hydrochloride; Shire) has been updated to include more information on how to use the medicine to treat children, following the completion of a paediatric investigation plan. 

  • Ofev approved by CHMP Subscription

    11 DEC 2014 13:18

    The Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, gave the orphan medicine Ofev (nintedanib; Boehringer Ingelheim) a positive opinion for the treatment of idiopathic pulmonary fibrosis.

  • Exviera and Viekira recommended by CHMP Subscription

    11 DEC 2014 11:10

    The Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, gave positive opinions for Exviera (dasabuvir; AbbVie) and Viekirax (ombitasvir, paritaprevir, ritonavir; AbbVie) for the treatment of chronic hepatitis C. Both products were reviewed under accelerated assessment and belong to a new generation of antiviral products for chronic hepatitis C infection that have high cure rates. 

  • Cerdelga approved by CHMP Subscription

    11 DEC 2014 11:09

    The Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has recommended granting a marketing authorisation for Cerdelga (eliglustat; Genzyme), an orphan medicine for the treatment of Gaucher disease type 1. 

  • Stelara side effects Subscription

    11 DEC 2014 11:04

    Skin exfoliation and exfoliative dermatitis have been added to the list of uncommon and rare side effects associated with Stelara (ustekinumab; Janssen-Cilag), respectively, in the medicine’s summary of product characteristics. If these symptoms occur, appropriate therapy should be instituted and ustekinumab discontinued. 

  • Eculizumab recommended by NICE Subscription

    11 DEC 2014 11:00

    The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending eculizumab (Soliris, Alexion) to treat the rare disease atypical Haemolytic Uraemic Syndrome (aHUS). The draft recommendation depends on certain arrangements being in place. Details can found on the NICE website.     

  • Nalmefene recommended by NICE Subscription

    11 DEC 2014 10:54

    Selincro (nalmefene; Lundbeck), a drug that can help people who are dependent on alcohol to cut down on the amount they drink, has been recommended by the National Institute for Health and Care Excellence (NICE). NICE says nalmefene should be available as a treatment for those who regularly drink large amounts of alcohol. The NHS is required to fund the treatment within ...

  • AS Saliva Orthana drug tariff change Subscription

    11 DEC 2014 10:48

    AS Saliva Orthana 50ml and 500ml sprays are now CE marked medical devices listed in Part IXA of the Drug Tariff. The AS Saliva Orthana product entry has been removed from Part XV (Borderline substances) of the Drug Tariff. This does not apply, however, to AS Orthana Lozenges and a separate entry will be reinstated under artificial saliva substitutes in the Part XVIIA of the January Drug Tariff. This will not affect reimbursement. 

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.